Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- Submitting institution
-
The University of Leicester
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 39
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(14)70023-3
- Title of journal
- Lancet Oncology
- Article number
- .
- First page
- 1007
- Volume
- 15
- Issue
- 9
- ISSN
- 1470-2045
- Open access status
- Out of scope for open access requirements
- Month of publication
- June
- Year of publication
- 2014
- URL
-
https://www.sciencedirect.com/science/article/pii/S1470204514700233?via%3Dihub
- Supplementary information
-
https://doi.org/10.1016/S1470-2045(14)70023-3
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
15
- Research group(s)
-
D - Cancer & pathology
- Citation count
- 186
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
